Faron Pharmaceuticals Oy
News & analysis
Times are shown in BST, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company developing novel treatments for medicalconditions. The company currently has a pipeline focusing on acute organ traumas,vascular damage and cancer immunotherapy.
Latest FARN News
FARN Regulatory News